**Table 2:** Blood pressure, heart rate, oxygen saturation, and sedation scores during the post-operative period in the ropivacaine group (R group) and in the ropivacaine + sufentanil group (RS group) for the intention-to-treat population.

|  |  |
| --- | --- |
|  | **Post-operative period, hours**  |
|  | 0 | 2 | 12 | 24 | 36 | 48 |
| **Blood pressure, mmHg, mean (SD)** |  |  |  |  |  |  |
|  R group (n=37) |  |  |  |  |  |  |
|  Systolic | 130 (22) | 118 (19) | 125 (19) | 127 (16) | 128 (15) | 127 (14) |
|  Diastolic | 75 (12) | 70 (14) | 75 (13) | 76 (12) | 80 (10) | 77 (11) |
|  RS group (n=33) |  |  |  |  |  |  |
|  Systolic | 121 (15) | 110 (14) | 117 (17) | 119 (18) | 123 (17) | 118 (14) |
|  Diastolic | 71 (11) | 60 (10) | 69 (11) | 69 (11) | 73 (10) | 71 (10) |
|  Total population (n=70) |  |  |  |  |  |  |
|  Systolic | 126 (19) | 114 (17) | 122 (18) | 123 (17) | 126 (16) | 123 (15) |
|  Diastolic | 73 (12) | 65 (13) | 72 (12) | 73 (12) | 77 (11) | 74 (11) |
| **Heart rate, bpm, mean (SD)** |  |  |  |  |  |  |
|  R group (n=37) | 81 (15) | 76 (14) | 77 (14) | 84 (16) | 84 (11) | 88 (12) |
|  RS group (n=33) | 88 (21) | 83 (17) | 83 (14) | 88 (14) | 85 (14) | 88 (12) |
|  Total population (n=70) | 84 (18) | 79 (16) | 80 (14) | 87 (15) | 85 (13) | 88 (12) |
| **Respiratory rate, brpm, mean (SD)** |  |  |  |  |  |  |
|  R group (n=37) | 19 (5.3) | 18 (5.1) | 18 (2.7) | 19 (4.3) | 18 (3.0) | 19 (3.9) |
|  RS group (n=33) | 19 (6.1) | 18 (4.9) | 19 (4.9) | 20 4.0) | 19 (4.2) | 19 (3.5) |
|  Total population (n=70) | 19 (5.7) | 18 (5.0) | 18 3.9) | 19 (4.1) | 19 3.7) | 19 (3.7) |
| **Oxygen saturation, %, mean (SD)** |  |  |  |  |  |  |
|  R group (n=37) | 97 (3.4) | 97 (2.9) | 97 (2.2) | 96 (1.9) | 95 (1.9) | 96 (1.5) |
|  RS group (n=33) | 98 (2.5) | 97 (2.8) | 95 (2.4) | 95 (2.3) | 95 (2.1) | 95 (2.5) |
|  Total population (n=70) | 98 (3.0) | 97 (2.9) | 96 (2.4) | 96 (2.1) | 95 (2.0) | 96 (2.0) |
| **Sedation score** |  |  |  |  |  |  |
|  R group (n=37), n (%) |  |  |  |  |  |  |
|  Awake and alert |  | 16 (43) | 25 (67) | 32 (87) | 30 (81) | 36 (97) |
|  Infrequently drowsy and easily aroused |  | 17 (46) | 11 (30) | 5 (14) | 7 (19) | 1 (3) |
|  Frequently drowsy but arousable |  | 4 (11) | 1 (3) | 0 | 0 | 0 |
|  Somnolent |  | 0 | 0 | 0 | 0 | 0 |
|  RS group (n=33), n (%) |  |  |  |  |  |  |
|  Awake and alert  |  | 18 (55) | 21 (64) | 31 (94) | 27 (82) | 33 (100) |
|  Infrequently drowsy and easily aroused |  | 14 (42) | 10 (30) | 2 (6) | 6 (18) | 0 |
|  Frequently drowsy but arousable |  | 1 (3) | 2 (6) | 0 | 0 | 0 |
|  Somnolent |  | 0 | 0 | 0 | 0 | 0 |

**Table 3:** Satisfaction scores at 48 hours in the ropivacaine group (R group) and in the ropivacaine + sufentanil group (RS group) for the intention-to-treat population.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Total population (n=70)** | **R group (n=37)** | **RS group (n=33)** |
| **Treatment satisfaction, n (%)** |  |  |  |
|  Very satisfied | 27 (40) | 14 (38) | 13 (42) |
|  Satisfied | 28 (41) | 18 (49) | 10 (32) |
|  No opinion | 6 (9) | 2 (5) | 4 (13) |
|  Unsatisfied | 3 (4) | 1 (3) | 2 (6) |
|  Very unsatisfied | 4 (5.9) | 2 (5) | 2 (6) |
|  Missing data | 2 | 0 | 2 |